	Monoclonal antibody
Therapy
Autoimmune disease
Treatment
Biological agent
Sjögren’s syndrome
	biological agents
pSS patients
treatment
clinical trials
weeks
effect
antibodies
disease duration 3
patients
cells
trials
clinical
antiCD
antiCD 20
improvement
VAS scores
II studies
dry eyes
side effects
pSS
active pSS
serum sickness-like disease
rituximab
promising results
disease progression
uncontrolled study
weeks 0
dry mouth
months
primary
randomized
salivary glands
salivary flow rate
score
infliximab
BAFF
infusions
results

